Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec;5(6):197-210.
doi: 10.1177/2040620714552614.

The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma

Claudia V Andreu-Vieyra  1 , James R Berenson  2
Affiliations
Review

The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma

Claudia V Andreu-Vieyra et al. Ther Adv Hematol. 2014 Dec.

Abstract

Panobinostat is an investigational and potent histone deacetylase inhibitor (HDACi) that has shown promise as an antimultiple myeloma agent in the preclinical setting. In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease.

Keywords: histone deacetylase inhibitor; multiple myeloma; panobinostat.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: J.R.B. is a member of the speaker’s bureau for Norvatis and acknowledges consulting and research funds from Novartis.

Figures

Figure 1.
Figure 1.
Histone deacetylase inhibitors (HDACis) block the deacetylation of both histone and nonhistone proteins, thereby causing transcriptional and protein activity changes. In multiple myeloma cells, such changes have been shown to lead to proteasome and aggresome inhibition, DNA damage and the upregulation of proapoptotic proteins, resulting in cell cycle arrest and apoptosis.
See this image and copyright information in PMC

References

    1. Aronson L., Davies F. (2012) DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica 97: 1119–1130. - PMC - PubMed
    1. Atadja P. (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280: 233–241. - PubMed
    1. Berdeja J., Mace J., Lamar R., Gian V., Murphy P., Patel M., et al. (2012) A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). J Clin Oncol 30: TPS8115.
    1. Berdeja J., Savona M., Mace J., Hart L., Essell J., Owera R., et al. (2013) A single-arm, open-label, multi-center phase I/II study of the combination of panobinostat and carfilzomib in patients (pts) with relapsed or relapse/refractory multiple myeloma (MM). Blood 122: 1937.
    1. Berenson J., Hilger J., Yellin O., Boccia R., Matous J., Dressler K., et al. (2014) A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol 93: 88–98. - PubMed